Top 10 Private Equity Investors: Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | Casdin Capital |
| 3 | Eli Lilly and Company |
| 4 | Janus Henderson Investors |
| 5 | Cormorant Asset Management |
| 6 | Redmile Group |
| 7 | Logos Capital |
| 8 | Wellington Management |
| 9 | Bristol-Myers Squibb |
| 10 | Deerfield Management |
Crossover funds that moved down from public markets appear alongside the traditional buyout franchises. Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.